Preventing CMV after heart transplant
Treatments studied
Part of Heart & circulation, Immune system & allergy, Infections clinical trials.
This trial compares two antiviral drugs, valganciclovir and letermovir, to see which works better at preventing CMV infection after a heart transplant. If you've had a heart transplant and haven't started preventive treatment yet, this study may be for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years.
- You have received a heart transplant.
- You have not yet started taking medication to prevent CMV infection.
- You have not had CMV disease or suspected CMV disease in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether the medicine letermovir can prevent a common viral infection (CMV) after a new heart transplant. It may help reduce CMV infection or illness in people who are at moderate to high CMV risk.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
This study compares a new antiviral drug (letermovir) to a standard one (valganciclovir) for preventing CMV infection after lung transplant. It is for people who are at high risk because the donor had CMV but the recipient did not.
This trial tests a new medicine, Leymovir, against a standard one, Valganciclovir, to prevent a common virus infection (CMV) after a first kidney transplant. It may help you avoid CMV-related illness.
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
Hear when a new CMV Viremia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.